Skip to main content

Table 5 Statistical difference ( P values) between the performance of PET/CT and cePET/CT for each analyzed tumor type, site of disease, and clinical question

From: Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

 

P value

Tumor type

 

Lung cancer

0.12

Head and neck cancer

0.02

Gastrointestinal cancera

0.0002

Breast cancer

0.09

Lymphoma

0.24

Melanoma

0.16

Multiple melanoma

0.08

Otherb

0.33

Site of disease

 

Neck

0.096

Thorax

0.36

Abdomen

0.009

Skeleton-bone marrow

0.33

Lymph nodes

0.44

Clinical question

 

Diagnosis

0.39

Staging

0.09

Restagingc

0.003

Response to chemotherapy

0.13

Response to radiotherapy

0.1

Post-surgery evaluation

0.54

Surveillance

0.51

  1. aIncluding esophageal, gastric, and colorectal cancer.
  2. bGynecologic malignancy n = 8 , testicular cancer n = 2, sarcoma n = 3, low-differentiated neuroendocrine carcinoma n = 4, thymoma n = 1.
  3. cSuspected relapse or patients with potentially resectable metastatic disease.
  4. PET, positron emission tomography; CT, computed tomography; cePET/CT, contrast-enhanced PET/ CT.